Hyperimmune goat serum for amyotrophic lateral sclerosis

Area of Science:

• Neurology
• Immunology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons.
• Respiratory muscle weakness is a primary cause of morbidity and mortality in ALS patients.

Observation:

• A single patient with ALS was treated with hyperimmune goat serum (HGS).
• Respiratory function tests (RFTs) were monitored over time to assess respiratory muscle strength.
• Measurements were standardized as a percentage of normal predicted values.

Findings:

• Respiratory muscle strength decline slowed significantly during 13 months of HGS treatment (1.3% per month) compared to the preceding 13 months (2.3% per month).
• The observed rate of decline under HGS treatment was notably less than expected for ALS progression and literature comparisons (4-5% decline per month).

Implications:

• Hyperimmune goat serum (HGS) may represent a potential therapeutic agent for slowing respiratory decline in ALS.
• Further research is warranted to validate these findings in a larger cohort of ALS patients.
• This study highlights the importance of monitoring respiratory function in ALS management.